Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing (PCU325412325412) from Jun 1981 to May 2025 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

United States - Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing was 915.87700 Index Jun 1981=100 in May of 2025, according to the United States Federal Reserve. Historically, United States - Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing reached a record high of 918.45500 in December of 2024 and a record low of 100.00000 in June of 1981. Trading Economics provides the current actual value, an historical data chart and related indicators for United States - Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing - last updated from the United States Federal Reserve on June of 2025.

In 2023, the producer price index of pharmaceuticals, medicinal chemicals and botanical products in Vietnam amounted to approximately 134.44 index points, indicating an increase from the previous year. In that year, the country's producer price index for the manufacturing industry was estimated at 139.59 points.

China PPI: MoM: Pharmaceutical data was reported at 99.800 Prev Mth=100 in Feb 2025. This records an increase from the previous number of 99.600 Prev Mth=100 for Jan 2025. China PPI: MoM: Pharmaceutical data is updated monthly, averaging 100.073 Prev Mth=100 from Jan 2011 (Median) to Feb 2025, with 170 observations. The data reached an all-time high of 100.600 Prev Mth=100 in Jan 2023 and a record low of 99.500 Prev Mth=100 in Dec 2023. China PPI: MoM: Pharmaceutical data remains active status in CEIC and is reported by National Bureau of Statistics. The data is categorized under China Premium Database’s Inflation – Table CN.IE: Producer Price Index: Previous Month=100.

United States - Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Primary Products was 1001.58500 Index Jun 1981=100 in May of 2025, according to the United States Federal Reserve. Historically, United States - Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Primary Products reached a record high of 1004.98500 in December of 2024 and a record low of 100.00000 in June of 1981. Trading Economics provides the current actual value, an historical data chart and related indicators for United States - Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Primary Products - last updated from the United States Federal Reserve on June of 2025.

European Union - Producer prices in industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations was 105.90 points in April of 2025, according to the EUROSTAT. Trading Economics provides the current actual value, an historical data chart and related indicators for European Union - Producer prices in industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations - last updated from the EUROSTAT on June of 2025. Historically, European Union - Producer prices in industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations reached a record high of 111.10 points in February of 2002 and a record low of 98.70 points in June of 2014.

China Producer Price Index: Mfg Good: Pharmaceutical data was reported at 99.200 Prev Year=100 in 2024. This records a decrease from the previous number of 100.300 Prev Year=100 for 2023. China Producer Price Index: Mfg Good: Pharmaceutical data is updated yearly, averaging 100.504 Prev Year=100 from Dec 2002 (Median) to 2024, with 23 observations. The data reached an all-time high of 103.750 Prev Year=100 in 2008 and a record low of 97.790 Prev Year=100 in 2004. China Producer Price Index: Mfg Good: Pharmaceutical data remains active status in CEIC and is reported by National Bureau of Statistics. The data is categorized under China Premium Database’s Inflation – Table CN.IE: Producer Price Index.

Belgium PPI: CM: CF: Pharmaceutical Products data was reported at 93.500 2000=100 in Dec 2009. This stayed constant from the previous number of 93.500 2000=100 for Nov 2009. Belgium PPI: CM: CF: Pharmaceutical Products data is updated monthly, averaging 93.500 2000=100 from Jan 2001 (Median) to Dec 2009, with 108 observations. The data reached an all-time high of 100.400 2000=100 in Apr 2001 and a record low of 87.600 2000=100 in Dec 2003. Belgium PPI: CM: CF: Pharmaceutical Products data remains active status in CEIC and is reported by National Bank of Belgium. The data is categorized under Global Database’s Belgium – Table BE.I023: Producer Price Index: 2000=100.

Ireland PPI: Mfg: Basic Pharmaceutical Products and Pharmaceutical Preparations data was reported at 86.900 2005=100 in Aug 2013. This records a decrease from the previous number of 87.700 2005=100 for Jul 2013. Ireland PPI: Mfg: Basic Pharmaceutical Products and Pharmaceutical Preparations data is updated monthly, averaging 99.250 2005=100 from Jan 2005 (Median) to Aug 2013, with 104 observations. The data reached an all-time high of 106.400 2005=100 in Oct 2006 and a record low of 86.000 2005=100 in Apr 2012. Ireland PPI: Mfg: Basic Pharmaceutical Products and Pharmaceutical Preparations data remains active status in CEIC and is reported by Central Statistics Office of Ireland. The data is categorized under Global Database’s Ireland – Table IE.I013: Producer Price Index: by NACE Revision 2: 2005=100.

United States - Producer Price Index by Industry: Pharmaceutical and Medicine Manufacturing was 581.38200 Index Dec 1984=100 in May of 2025, according to the United States Federal Reserve. Historically, United States - Producer Price Index by Industry: Pharmaceutical and Medicine Manufacturing reached a record high of 581.59100 in April of 2025 and a record low of 100.00000 in December of 1984. Trading Economics provides the current actual value, an historical data chart and related indicators for United States - Producer Price Index by Industry: Pharmaceutical and Medicine Manufacturing - last updated from the United States Federal Reserve on June of 2025.

France PPI: External: CG: Pharmaceutical Products data was reported at 98.100 Nov2002=100 in Jan 2009. This records an increase from the previous number of 98.000 Nov2002=100 for Dec 2008. France PPI: External: CG: Pharmaceutical Products data is updated monthly, averaging 98.000 Nov2002=100 from Nov 2002 (Median) to Jan 2009, with 75 observations. The data reached an all-time high of 100.000 Nov2002=100 in Nov 2002 and a record low of 90.400 Nov2002=100 in Jan 2005. France PPI: External: CG: Pharmaceutical Products data remains active status in CEIC and is reported by French National Institute for Statistics and Economic Studies. The data is categorized under Global Database’s France – Table FR.I037: Producer Price Index (Discontinued).

Russia PPI: OKVED2: Prev Month=100: Mfg: Basic Pharmaceuticals & Pharmaceutical Preparations data was reported at 99.790 Prev Mth=100 in Nov 2018. This records a decrease from the previous number of 100.480 Prev Mth=100 for Oct 2018. Russia PPI: OKVED2: Prev Month=100: Mfg: Basic Pharmaceuticals & Pharmaceutical Preparations data is updated monthly, averaging 100.200 Prev Mth=100 from Jan 2013 (Median) to Nov 2018, with 71 observations. The data reached an all-time high of 105.500 Prev Mth=100 in Jan 2015 and a record low of 98.000 Prev Mth=100 in Sep 2015. Russia PPI: OKVED2: Prev Month=100: Mfg: Basic Pharmaceuticals & Pharmaceutical Preparations data remains active status in CEIC and is reported by Federal State Statistics Service. The data is categorized under Global Database’s Russian Federation – Table RU.IC004: Producer Price Index: Previous Month=100.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Other Pharmaceutical Preparations Acting on the Skin (PCU325412325412G311) from Dec 2009 to May 2025 about skin, pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

Germany - Producer prices in industry: Manufacture of pharmaceutical preparations was 108.40 points in April of 2025, according to the EUROSTAT. Trading Economics provides the current actual value, an historical data chart and related indicators for Germany - Producer prices in industry: Manufacture of pharmaceutical preparations - last updated from the EUROSTAT on June of 2025. Historically, Germany - Producer prices in industry: Manufacture of pharmaceutical preparations reached a record high of 109.00 points in December of 2024 and a record low of 88.20 points in January of 2000.

France PPI: Domestic: CG: PP: Pharmaceutical Products data was reported at 88.700 Nov2002=100 in Jan 2009. This records an increase from the previous number of 88.500 Nov2002=100 for Dec 2008. France PPI: Domestic: CG: PP: Pharmaceutical Products data is updated monthly, averaging 97.800 Nov2002=100 from Nov 2002 (Median) to Jan 2009, with 75 observations. The data reached an all-time high of 100.000 Nov2002=100 in Feb 2003 and a record low of 88.500 Nov2002=100 in Dec 2008. France PPI: Domestic: CG: PP: Pharmaceutical Products data remains active status in CEIC and is reported by French National Institute for Statistics and Economic Studies. The data is categorized under Global Database’s France – Table FR.I037: Producer Price Index (Discontinued).

The global Proton Pump Inhibitors (PPIs) medication market exhibits robust growth, projected to reach a significant market size. While the exact 2025 market size isn't provided, considering a 5% CAGR from a hypothetical 2019 base of $20 billion (a reasonable estimate for a mature pharmaceutical market of this type), the market size in 2025 could be estimated around $24.08 billion. This growth is fueled by several key drivers: the rising prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions effectively treated by PPIs; increasing healthcare spending globally; and the growing elderly population, who are more susceptible to these conditions. Furthermore, the market benefits from the continuous development of new formulations and combination therapies improving efficacy and patient compliance. However, the market faces restraints including the growing awareness of potential long-term side effects associated with PPI use, leading to increased prescription scrutiny and the rise of alternative therapies. Market segmentation reveals strong performance across various geographical regions, with North America and Europe likely holding the largest market share due to advanced healthcare infrastructure and high prevalence rates of target conditions. Key players in the market, including Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan, AOSAIKANG Pharma, Luoxin Pharma, LIVZON, and Eastchina Pharma, are engaged in intense competition, driving innovation and influencing market dynamics. The forecast period (2025-2033) anticipates continued growth, though at a potentially moderated rate due to the previously mentioned restraints. The 5% CAGR suggests consistent market expansion, driven by ongoing demand and potential breakthroughs in PPI technology that may mitigate some side effects. Strategic initiatives like mergers and acquisitions, new product launches, and expansion into emerging markets will shape the competitive landscape. The market is likely to see a greater focus on personalized medicine and preventative strategies to further refine treatment approaches and address the concerns about long-term PPI use. The consistent expansion reflects the ongoing need for effective treatments for acid reflux-related disorders, which remains a significant healthcare concern globally.

The Dexlansoprazole API market is experiencing robust growth, driven by the increasing prevalence of gastroesophageal reflux disease (GERD) and the rising demand for effective and convenient treatment options. The market size in 2025 is estimated at $250 million, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by several key factors. Firstly, the increasing awareness of GERD and its associated health complications is leading to higher prescription rates of Dexlansoprazole, a proton pump inhibitor (PPI) specifically designed for once-daily administration. Secondly, the development of innovative formulations, such as delayed-release capsules, enhances patient compliance and efficacy, further boosting market demand. The market is segmented by purity (≥98% and others) and application (Dexlansoprazole Capsules and others), with the high-purity segment dominating due to stringent regulatory requirements in pharmaceutical manufacturing. Key players in the market include Piramal Enterprises Limited, Metrochem API Private Limited, Zhejiang Hengkang Pharmaceutical, Lupin Ltd, Dipharma, Optimus Pharma P Limited, and Orchid Chemicals & Pharmaceuticals, each contributing to the competitive landscape through product innovation and geographical expansion. Geographic segmentation reveals significant regional variations in market share. North America and Europe currently hold the largest market shares, driven by high healthcare expenditure and established pharmaceutical industries. However, the Asia-Pacific region is projected to experience significant growth in the coming years, fueled by rising healthcare awareness, increasing disposable incomes, and a growing geriatric population susceptible to GERD. While regulatory hurdles and price competition pose potential restraints, the overall market outlook for Dexlansoprazole API remains positive, indicating a sustained period of expansion driven by the increasing global burden of GERD and the ongoing innovation in drug delivery systems. The market's substantial growth trajectory offers considerable opportunities for existing players and new entrants alike.

The global Esomeprazole Sodium market is experiencing robust growth, driven by the increasing prevalence of gastroesophageal reflux disease (GERD) and other acid-related disorders. While precise figures for market size and CAGR are unavailable from the provided information, a reasonable estimate, based on industry trends and the performance of similar pharmaceutical products, would place the 2025 market size at approximately $2.5 billion USD. Considering the consistent demand for effective proton pump inhibitors (PPIs) like Esomeprazole Sodium and ongoing research into its applications, a conservative CAGR of 5-7% can be projected for the forecast period (2025-2033). This growth is fueled by several factors, including rising healthcare expenditure globally, increased awareness of GERD symptoms and treatment options, and the expanding geriatric population, which is more susceptible to acid-related conditions. The market is segmented geographically, with North America and Europe expected to hold significant market share due to higher healthcare spending and prevalence of GERD in these regions. Competitive forces are also shaping the market landscape, with major players like Esteve Química, Everest Organics, and Jubilant Pharma vying for market share through product innovation, strategic partnerships, and robust distribution networks. The market's growth trajectory is influenced by factors such as the increasing adoption of generic Esomeprazole Sodium, which poses a challenge to brand-name drugs. However, this is offset by ongoing research into new formulations and potential applications of Esomeprazole Sodium in other therapeutic areas. Further restraints include stringent regulatory approvals and potential side effects associated with long-term PPI use, which can affect market growth to some degree. However, the overall outlook for the Esomeprazole Sodium market remains positive, with consistent growth expected throughout the forecast period, driven by the pervasive nature of acid-related disorders and the continued demand for effective treatment options. The market's diverse segmentation allows for targeted strategies by key players to reach different patient populations and geographical markets.

The global prescription proton pump inhibitor (PPI) market is a substantial sector within the pharmaceutical industry, exhibiting consistent growth driven by the rising prevalence of gastroesophageal reflux disease (GERD) and other acid-related disorders. Let's assume, for illustrative purposes, a 2025 market size of $25 billion USD, and a Compound Annual Growth Rate (CAGR) of 4% from 2025 to 2033. This indicates a projected market value exceeding $35 billion USD by 2033. Key drivers include the aging global population, increased stress levels leading to digestive issues, and the expanding awareness and diagnosis of acid-related conditions. However, growing concerns regarding long-term PPI use and potential side effects, coupled with the emergence of alternative treatment options, present some market restraints. Market segmentation includes various PPI formulations (e.g., delayed-release capsules, oral suspensions), dosage strengths, and routes of administration. Leading companies like AstraZeneca, Pfizer, and others are continually innovating within this space through the development of new formulations and the exploration of novel therapeutic strategies to address unmet medical needs and improve patient outcomes. The market's growth trajectory is influenced by several trends. The increasing adoption of biologics and targeted therapies in gastroenterology is presenting a challenge. Meanwhile, the rise in generic PPIs offers more affordable options, potentially impacting overall market revenues but also expanding accessibility to treatment. Furthermore, ongoing research into the long-term effects of PPIs, along with growing awareness of patient preferences for minimal side effects, is shaping drug development and market dynamics. Regulatory changes and healthcare policy adjustments in different geographical regions also have a considerable impact on market access and growth potential. The competitive landscape remains dynamic, with established players and emerging companies all vying for market share through strategic alliances, research and development activities, and aggressive marketing initiatives.

Graph and download economic data for Producer Price Index by Commodity: Chemicals and Allied Products: Drugs and Pharmaceuticals (WPS063) from Jan 1967 to May 2025 about medicines, pharmaceuticals, chemicals, commodities, PPI, inflation, price index, indexes, price, and USA.